Synthetic T3 thyroid hormone
Liothyronine
Direct thyroid-hormone (T3) with faster onset than T4 replacement.
Primary Mechanism of Action
Clinical / Scientific
Liothyronine is T3 and binds thyroid hormone receptors without requiring deiodinase activation. Nuclear TR signalling then alters metabolic and cardiovascular gene expression more rapidly than T4.
Pathway Targets
Thyroid hormone receptors
Scientific explanation
Direct T3 agonism.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Direct TR activation
Target to downstream effect: T3–TR binding → Thyroid-response-element transcription → Increased metabolic rate
Mechanistically Relevant Repurposed & Adjunctive Applications
Selected hypothyroidism / myxoedema protocols
EstablishedMechanistic rationale
Established T3 medicine; not first-line monotherapy for most primary hypothyroidism.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| TRα/TRβ | Direct agonism | Metabolic gene transcription | Established mechanism |
Mechanistic Interaction Considerations
High arrhythmia and bone-turnover risk if over-replaced. Additive with levothyroxine. Catecholamine sensitivity increases.
In Plain Language
Liothyronine is ready-made T3 — the active thyroid message — so it acts faster than T4, and dosing mistakes show up faster too.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
Thyroid hormone receptors
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.